Quarterly narrative also stated the following:
'There is a risk that NanoDX may not satisfy the FDA’s requirements for an EUA and/or the evaluation of NanoDX’s EUA submission may take longer than expected.'
None of that nonsense was written in today's half yearly which stated:
'The Group has engaged in a material agreement that will be fully disclosed once the sensor reaches FDA approval.'
A positive change in language used and it makes zero sense not to go through the EUA process. If that had changed Sensera would have announced it.
Cheers
SE1 Price at posting:
8.0¢ Sentiment: Buy Disclosure: Held